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Background
Prophylactic vaccine strategies against HIV-1 must
effectively prevent virus transmission, infection and cell-
to-cell spread during the earliest stages of acute infec-
tion. Since the genital mucosa is the primary site of
entry, mucosal defense is critical for early control of
infection. Recent identification of transmitted/founder
(T/F) HIV-1 genomes has demonstrated a consistent
genetic bottleneck during mucosal transmission and
suggests that T/F viruses may exhibit distinct pheno-
types. HIV-1 Env gp41-specific responses are among the
first to be generated in natural HIV infection.
Methods
Previously, we developed chimeric virus-like particle
(VLP) immunogens that elicit potent systemic and muco-
sal antibodies against two highly conserved regions of
gp41, by employing an optimized immunization strategy.
The ELDKWA and QARVLAVERY epitopes are found
with the membrane proximal external region (MPER)
and the coiled coil region of gp41, respectively. Impor-
tantly, the epitope-specific IgG and IgA fractions derived
from immunized mice were shown to be effective in neu-
tralizing and preventing transcytosis of HIV in vitro. In
particular, the QARVLAVERY epitope is remarkably con-
served and induced unusually high and early levels of
anti-QARV IgA, making it an attractive candidate for
generation of broadly reactive mucosal antibodies.
Results
In this study, we assessed the effectiveness of mucosal
and systemic mouse antibodies elicited against these
gp41 epitopes to inhibit T/F Env function. For this, we
employed recombinant infectious molecular clones
(Env-IMC) of HIV-1 that encode mucosally transmitted/
founder env genes. Our results show that the gp41-spe-
cific IgG and IgA fractions effectively prevented the
infection of TZM-bl cells and inhibited HIV transcytosis
in an assay measuring the passage of infectious virus
across an epithelial monolayer. Interestingly, the T/F
Env-IMC tested were more sensitive to the antibodies
than the R5 lab-adapted strains included as controls.
Conclusion
These results highlight the potential of gp41-based
immunogens to impart effective mucosal protection in
the earliest stages of HIV transmission and infection.
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